Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

PALO ALTO, Calif., Dec. 2 Intradigm Corporation, a leadingdeveloper of targeted, systemic RNA interference (RNAi) therapeutics, todayannounced the issuance of United States patent 7,459,547, entitled "Methodsand Compositions for Controlling Efficacy of RNA Silencing." The issuedpatent, which is based on the seminal research of Philip Zamore, Ph.D., theGretchen Stone Cook Chair of Biomedical Sciences and Professor of Biochemistry& Molecular Pharmacology at University of Massachusetts Medical School,generally claims methods of enhancing the RNA silencing activity of an RNAiagent through certain structural modifications in various cell types,including mammalian. The issued claims not only focus on siRNA but alsoinclude specific claims directed to micro RNA (miRNA), pre-miRNA, and shorthairpin RNA (shRNA). This patent issues from a portfolio of severalapplications disclosing efficacy-enhancing methods and structural elements ofRNAi therapeutics that Intradigm has exclusively licensed from the Universityof Massachusetts Medical School.

"There is little dispute among those involved in the RNAi sector thatproper siRNA structure and design is taking on an increasingly important rolein the development of next generation RNAi therapeutics," said James Topper,M.D., Ph.D., general partner at Frazier Healthcare Ventures and chairman ofIntradigm's board of directors. "Accordingly, the siRNA structure claims ofthis issued patent provide Intradigm with another important tool in thecompany's efforts to realize the tremendous therapeutic promise of RNAinterference."

"Ongoing scientific research has highlighted the importance of siRNAstructure as a critical component of an effective RNAi therapeutic and theissuance of this patent provides Intradigm with a significant competitiveadvantage in this area," said Mike Riley, Intradigm's vice president ofintellectual property and corporate development. "For Intradigm, this patentbecomes even more valuable when combined with the company's proprietary RNAisequences and delivery technologies. Ultimately, access to this intellectualproperty will allow Intradigm to create a high value pipeline of well-protected products developed by incorporating novel, enhanced RNAi sequencesinto the company's innovative RNAi delivery systems."

Intradigm possesses one of the industry's strongest RNAi IP positionsincluding key assets strategically licensed from both the University ofMassachusetts Medical School and the Massachusetts Institute of Technology(MIT). The company's IP estate of issued patents and pending applicationsbroadly covers structural features for a next generation of RNAi molecules,biodegradable polycationic polymers for the delivery of RNAi therapeutics, andproprietary siRNA sequence applications.

ABOUT INTRADIGM

Intradigm is a private biotechnology company committed to the discovery,development and delivery of targeted, systemic RNA interference (RNAi)therapeutics for the treatment of serious diseases with an initial focus ononcology. Intradigm is unique, among private companies, with its comprehensiveRNAi therapeutics platform consisting of structural features for next-generation of RNAi molecules, biodegradable polycationic polymers for thedelivery of RNAi therapeutics and proprietary siRNA sequence applications. Ourproprietary delivery technology is unique in its potential to offer safe andeffective systemic administration using a library of novel peptide-basedbiodegradable polymers.

We have established an impressive proprietary portfolio of siRNA sequencesagainst more than 50 highly valued oncology and other disease targets. Inaddition, we have secured an exclusive license to the Zamore patent familyfrom the University of Massachusetts, which covers broad structural featuresof siRNA design for more potent next generation siRNA sequences. Our goal isto grow Intradigm to become a leading company in enabling the development ofnovel RNAi therapeutics against a broad range of therapeutic targets using oursiRNA sequences and delivery technology.

For more information on Intradigm, please visit http://www.intradigm.com.

SOURCE Intradigm Corporation

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...